GLP-1 low-dose psychiatric protocol prevents anhedonia through ketogenic diet pairing at 0.6mg weekly tirzepatide
Quarter-dose tirzepatide (0.6mg weekly) paired with ketogenic diet achieves psychiatric benefits without emotional blunting in ~100-patient cohorts
Claim
Dr. Bosworth and Dr. Albright report no emotional blunting in approximately 100-patient cohorts using low-dose tirzepatide at 0.6mg weekly — one-quarter the standard 2.5mg starting dose — paired with ketogenic diet. The protocol includes structured resistance training and adequate protein intake (1.6-2.3g/kg/day) to prevent lean mass loss. Monitoring uses the 'Dr. Boz Ratio' (blood glucose ÷ blood ketones): >80 indicates glucose metabolism, 40-80 moderate ketosis, <40 deeper therapeutic ketosis. This represents a distinct psychiatric dosing strategy compared to standard metabolic dosing. The absence of anhedonia at this dose supports the tonic vs. phasic receptor activation mechanism: lower doses may preserve phasic signaling patterns while higher doses create sustained tonic suppression. The ketogenic pairing may provide metabolic support that allows lower GLP-1 doses to achieve psychiatric effects. This is the most concrete psychiatric prescribing protocol available as of March 2026, developed in clinical practice before formal guidelines exist.
Sources
1- 2026 05 07 osmind glp1 psychiatric drugs competency
inbox/queue/2026-05-07-osmind-glp1-psychiatric-drugs-competency.md
Reviews
1## Leo's Review **1. Schema:** All four files are type:claim with complete frontmatter including type, domain, description, confidence, source, created, title, agent, sourced_from, scope, and sourcer—schema is valid for claim type. **2. Duplicate/redundancy:** The new claims introduce distinct evidence (Bosworth/Albright 0.6mg protocol, Dr. Boz Ratio monitoring, Sauvé's competency framing) that does not duplicate existing content; enrichments to existing claims add new sources (Osmind synthesis, Sauvé quote) rather than repeating evidence already present. **3. Confidence:** All four new claims use "experimental" confidence, which is appropriate given they rely on clinical cohort observations (~100 patients) and practitioner protocols rather than RCT evidence, though the Bosworth/Albright cohorts are small and lack formal publication. **4. Wiki links:** The PR references `[[glp1-psychiatric-dose-response-data-absent-despite-mechanistic-evidence]]` in related fields, which appears to be a broken link (not in changed files), but this is expected per instructions and does not affect approval. **5. Source quality:** Sources include named clinicians (Dr. Bosworth, Dr. Albright, Dr. Sauvé as Osmind CMO) with specific clinical cohorts and protocols, plus published trials (Hendershot JAMA Psychiatry, Lilly Phase 3, All of Us) for the AUD enrichment—credible for experimental-confidence claims. **6. Specificity:** Each claim is falsifiable: the 0.6mg dose claim could be contradicted by cohorts showing emotional blunting at that dose; the Dr. Boz Ratio thresholds (>80, 40-80, <40) are concrete numerical targets; the competency gap claim could be falsified by evidence of systematic psychiatric monitoring in primary care GLP-1 prescribing. <!-- VERDICT:LEO:APPROVE -->